HR 679 · 119th Congress
To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.
This bill would reverse changes that the FDA made in January 2023 to how the abortion pill mifepristone can be distributed and used. In 2023, the FDA relaxed its rules for this medication, making it easier for people to access by allowing it to be dispensed through regular pharmacies with mail delivery, rather than…
- Sponsor
- Harshbarger, Diana (R-Tennessee)
- Introduced
- 2025-01-23
- Policy area
- Health
- Latest action
- Referred to the House Committee on Energy and Commerce.
Digging through Congress... 🔍